Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Graciela Uranga"'
Autor:
Javier Crisci, Mariano Moro, Jorge A Nefa, Luciana Olivero, Sebastián Piaggio, José Mella, Lucio Uranga, Lisandro Alle, Marcela Carballido, Lucas Esteban Granero, Eduardo Mullen, María Laura Vergara, Oscar Mazza, Mirta Kujaruk, Hui Jer Hwang, Pablo Capitanich, Anabel Villagra, Elisa Panelli, Graciela Uranga, Nicolás Muñoz, Mariano Volpacchio, Analia Pasqua, Silvia C. Gutierrez, Eduardo Javier Houghton, Natalia Zavaroni, Diego Fernández, Zohar Jastreblansky, Tomás Lancelotti, Federico Cayol, Sandra Basso, Federico H. Marcaccio, Gustavo Kohan, Juan Carlos Spina, Marisa Canicoba
Publikováno v:
Acta gastroenterológica latinoamericana. 50
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5523d659b83a10cd452385482432f54
https://doi.org/10.52787/xaqm8690
https://doi.org/10.52787/xaqm8690
Autor:
NADIA, PIRES, LUISINA, FRUCI, JÉSICA, MONZÓN, GASTON, BOGGIO, GRACIELA, URANGA, CARLOS, LOVESIO
Publikováno v:
Revista Médica de Rosario; may-ago2019, Vol. 85 Issue 2, p67-70, 4p
Autor:
Francisco Lastiri, Marcelo Muino, José Luis Castilla, S. Jovtis, Luis Balbiani, Mariana Abal, Roberto Pinckevicius, Adolfo Marantz, D. Lewi, Silvia Agusto, Eduardo Almira, Graciela Pasccon, Graciela Uranga, Luis Fein, Mónica Reale
Publikováno v:
Seminars in Oncology. 28:44-49
The primary goal of this phase II study was to determine the efficacy of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) plus 5-fluorouracil in patients with pancreatic cancer. Eligibility criteria included nonresectable locally advance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::afdd06435c283d0bba23ac99a62798be
https://doi.org/10.1016/s0093-7754(01)80008-7
https://doi.org/10.1016/s0093-7754(01)80008-7
Autor:
NADIA, PIRES, LUISINA, FRUCI, JÉSICA, MONZÓN, GASTON, BOGGIO, GRACIELA, URANGA, CARLOS, LOVESIO
Publikováno v:
Revista Médica de Rosario; mai-ago2018, Vol. 84 Issue 2, p67-70, 4p
Autor:
Adolfo Marantz, Silvia Jovtis, Eduardo Almira, Luis Balbiani, Jos[eacute] Luis Castilla, Luis Fein, Daniel Lewi, Graciela Pasccon, Roberto Pinckevicius, Graciela Uranga, Mariana Abal, Marcelo Mui[ntilde]o, M[oacute]nica Reale, Silvia Agusto
Publikováno v:
Seminars in oncology. 28(3 Suppl 10)
The primary goal of this phase II study was to determine the efficacy of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) plus 5-fluorouracil in patients with pancreatic cancer. Eligibility criteria included nonresectable locally advance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d652cee753cd9e5f520a8770a59e6936
https://pubmed.ncbi.nlm.nih.gov/11510033
https://pubmed.ncbi.nlm.nih.gov/11510033